ersonal use only

Investor Briefing

H1 FY22

RESULTS

28 February 2022

Martin Perelman

Founder & MD

Ivan Jacques

CFO

SILK Group H1 FY22 results highlights

onlyuse ersonal2

$76.4m $40.5m $12.7m

Network cash sales

Revenue

Pro forma EBITDA

+70% vs PCP

+32% vs PCP

+20% vs PCP

$5.7m $4.1m +7%

Pro forma NPAT1

Statutory NPAT

Like-for-like growth of

+2% vs PCP

network cash sales

H1 FY22 includes ASC/TCC from 1/9/21. Network cash sales adjusted for lost trading days.

Note1: Pro-forma NPAT net of Non Controlling Interest.

This slide is not referring like-for-like - refer to slide 8 for breakdown

Integration of ASC/TCC progressing as planned

onlyuse ersonal3

Skincare products

ASC's skincare distribution business now fully integrated

SILK's ARx premium range being introduced to ASC clinics

NZ regulatory approval being sought for SILK's Medipen device

Supporting the franchise network

SILK's franchisee support and sales culture is being introduced and has been well received

SILK daily dashboards being rolled out in ASC with positive response from franchisees

Operational efficiencies

Finance & HR support functions combined.

Investing $1.5m to $2.0m in an upgrade of HR, Finance and POS platforms in H2

Review of procurement tendering to harmonise injectable offerings and supplier pricing

Significant opportunities to leverage SILK's partnership with Allergan and introduce Coolsculpting to ASC/TCC

Injectables

Product offering, franchise margins, retail price points and packages being aligned

Medipen to be rolled out across ASC Network in H2 FY22

Strong bounceback in Q2 FY22

Q1 FY22 impacted by lost trading days as a result of COVID lockdowns.

only

Sales rebounded well in Q2 FY22 post opening and have returned to normal, consistent levels after a

6- 8 week bounce back.

Online training implemented during lockdowns to keep staff engaged and up-to-date with

best practices.

use

Weekly sales

ersonal

Weekly days traded

4

"SILK helped us pull the business together so we could trade through the uncertainty, keep our staff engaged and ensure both our team and our customers were safe."

Nurse Cher , Prospect SA

onlyuseOperational strategy ersonaltranslating to

financial results

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Silk Laser Australia Ltd. published this content on 27 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 February 2022 22:11:10 UTC.